درباره این اپیزود
Join Ropes & Gray’s life sciences and health care attorneys for a podcast series exploring regulatory, compliance, and enforcement changes emanating from Washington, D.C. and the potential impact on life sciences companies in 2024. In this second episode, we focus on key issues to watch related to product development, approval, and drug pricing in 2024. These include FDA activities aimed at expediting the development of drugs to treat rare diseases, changes to FDA’s accelerated approval program, clinical trial diversity initiatives, actions to support use of real-world evidence, and developments in drug pricing and market access as CMS works to implement the Medicare Price Negotiation Program and prepares for the Medicare Part D redesign.
انگلیسی
ایالات متحده آمریکا
رونوشت 🔗
Kellie Combs: Hello, and welcome to Non-binding Guidance, our 2024 U.S. life sciences regulatory outlook podcast series. I’m Kellie Combs. I’m a partner in the life sciences regulatory and compliance practice group at Ropes & Gray based in D.C. I’m joined today by my colleague Sarah Blankstein, also in our life sciences regulatory and compliance group based in Boston, and Margaux Hall, a partner in our health care practice based with me in Washington.
Today, we’ll focus on anticipated developm…
Today, we’ll focus on anticipated developm…
جستجوی اپیزودهای گذشته
اپیزودهای قبلی Non-binding Guidance را جستجو کن.
سلب مسئولیت: پادکست و آثار هنری تعبیه شده در این صفحه متعلق به Ropes & Gray LLP است که متعلق به صاحب آن است و به Listen Notes، Inc وابسته یا تایید نشده است.
ویرایش
از کمک شما برای بروز نگهداشتن پایگاهدادههای پادکست سپاسگزاریم